Serum prohepcidin concentrations at birth and 1 month after birth in premature infants

Junko Kitajima1, Shouichi Ohga, Tadamune Kinjo

  • 1Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Pediatric Blood & Cancer
|September 11, 2010
PubMed

Insights

Premature newborns have lower serum prohepcidin at birth, indicating immature iron regulation. Postnatal increases suggest adaptation of iron homeostasis in preterm infants.

Area of Science:

  • Neonatal Medicine
  • Pediatric Hematology
  • Iron Metabolism

Background:

  • Premature newborns exhibit vulnerability to iron imbalances.
  • Iron homeostasis during the perinatal period requires further clarification.
  • Understanding iron metabolism in preterm infants is crucial.

Purpose of the Study:

  • To investigate serum prohepcidin concentrations in preterm infants.
  • To analyze the association between prohepcidin levels and iron parameters.
  • To clarify iron metabolism in premature neonates.

Main Methods:

  • Enrolled 71 infants (61 preterm, 10 term) without underlying diseases.
  • Measured serum prohepcidin concentrations at birth and 1 month postnatally.
  • Utilized enzyme-linked immunosorbent assay for prohepcidin determination.

Main Results:

  • Prohepcidin levels at birth correlated positively with gestational age and birth weight.
  • Preterm infants had lower birth prohepcidin levels than term infants, with a subsequent increase.
  • Prohepcidin levels at birth correlated with red cell counts, iron binding capacity, protein, albumin, and serum iron, but not ferritin.
  • Lower birth prohepcidin was associated with pregnancy-induced hypertension and premature rupture of membranes.

Conclusions:

  • Prohepcidin production is physiologically low at birth in preterm infants, influenced by gestational age.
  • In utero stress may affect prohepcidin levels.
  • Postnatal increases in prohepcidin may indicate maturation and adaptation of iron homeostasis.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...